Fulltext

A comparison of enoxaparin with unfractionated heparins in patients with coronary heart disease in an emergency department in rural South Indian tertiary care teaching hospital

Ahmad A 1 , Patel I 2 , Asani H 3 , Jagadeesan M 3 , Parimalakrishnan S 3 , Selvamuthukumaran S 4

Affiliations 

  • 1 Department of Clinical Pharmacy, Faculty of Pharmaceutical Sciences, UCSI University, No. 1 Jalan Menara Gading, UCSI Heights, Cheras 56000, Kuala Lumpur, Malaysia ; Department of Pharmacy Practice, Annamalai University, Tamil Nadu, India
  • 2 Department of Biopharmaceutical Sciences, Shenandoah University, Winchester, VA, USA
  • 3 Department of Pharmacy Practice, Annamalai University, Tamil Nadu, India
  • 4 Department of Medicine, Rajah Muthiah Medical College and Hospital, Annamalai University, Tamil Nadu, India
Indian J Pharmacol, 2015 Jan-Feb;47(1):90-4.
PMID: 25821318 DOI: 10.4103/0253-7613.150360

Abstract

Antithrombotic therapy with heparin plus antiplatelets reduces the rate of ischemic events in patients with coronary heart disease. Low molecular weight heparin has a more predictable anticoagulant effect than standard unfractionated heparin, is easier to administer, does not require monitoring and is associated with less ADRs. The purpose of the present study was to evaluate and compare the clinical and cost outcomes of Enoxaparin with a standard unfractionated heparin in patients with coronary heart disease.

* Title and MeSH Headings from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

MeSH terms
Similar publications